Barclays analyst Gena Wang lowered the firm’s price target on Avidity Biosciences (RNA) to $57 from $63 and keeps an Overweight rating on the shares. The company’s Q4 report was largely incremental, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
- Avidity Biosciences reports Q4 EPS (80c), consensus (78c)
- Avidity Biosciences: Undervalued Entry Point with Promising 2025 Pipeline Despite Market Challenges
- Chardan unveils four top biotech picks for 2025
- Avidity Biosciences plans BLA submission for delpacibart zotadirsen